Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Pre- and postoperative positive expiratory pressure (PEP) chest therapy to prevent hospital-acquired pneumonia

Official title: Pre- and Postoperative Chest Therapy With Positive Expiratory Pressure (PEP) to Prevent Hospital-acquired Pneumonia in Patients Undergoing Hip Fracture Surgery

Run by University Hospital Bispebjerg and Frederiksberg · NCT07189260 · Data updated 2026-11-12

This will see if using positive expiratory pressure (PEP) chest therapy before and after hip fracture surgery prevents hospital-acquired pneumonia in patients who can give informed consent.

More Hip Fractures (ICD-10 72.01-72.2) trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment566 (estimated)
SponsorUniversity Hospital Bispebjerg and Frederiksberg
Academic / other
Locations2 sites (Copenhagen and 1 other locations)
StatusRecruiting
StartedFebruary 19, 2024
Main results expectedDecember 31, 2029
Study endsDecember 31, 2030
Registry record updatedSeptember 23, 2025
Trial IDNCT07189260 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are cognitively well-functioning adults with a hip fracture who can understand Danish, give informed consent, and are residents of Region Hovedstaden or Region Sjælland.

Probably not a fit

Patients with existing pneumonia, delirium, pneumothorax, or those unable to consent or perform the therapy are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional study compares systematic PEP chest therapy given before and after surgery with usual care alone in patients admitted with a hip fracture. Participants in the PEP arm will be asked to perform PEP therapy four times daily during hospitalization and log each session and any reasons for missed sessions on a paper checklist. The trial excludes patients with pneumonia or delirium on admission, pneumothorax, or those unable to consent, and enrolls cognitively well-functioning Danish-speaking residents of two Danish regions. Investigators will also collect information on barriers to performing PEP therapy in this patient group.

Why it matters

Potential benefit: If successful, the approach could reduce the number of hospital-acquired pneumonia cases after hip fracture and lower related complications and hospital stays.

How similar studies have gone: Some perioperative respiratory-therapy trials (mainly after abdominal or thoracic surgery) have shown reduced pulmonary complications, but evidence specifically in hip-fracture patients is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Hip fracture regardless of age
* Cognitively well-functioning
* Able to understand the study and give informed consent
* Able to speak and understand Danish
* Resident of Region Hovedstaden or Region Sjælland

Exclusion Criteria:

* Cognitively impaired
* Unable to understand the study and give informed consent
* Pneumonia upon admission
* Delirium upon admission
* Pneumothorax

For patients with e.g. dementia or brain injury, the ability to give informed consent will be assessed individually.

Where it's running

  • Bispebjerg & Frederiksberg Hospital
    Copenhagen, Denmark
    Recruiting
  • Herlev & Gentofte Hospital
    Herlev, Denmark
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.